Discover
ARWR
Arrowhead Pharmaceuticals, Inc.
62.75
2 x 56.95
2 x 66.03
bid
ask
+
2.01
3.31%
2 @ 04:23 PM
62.75 +0.00 (0.00%)
| Ytd | -5.48% | |
| 1y | 74.02% |
60.48
day range
62.99
35.41
52 week range
89.59
| Open | 60.72 | Prev Close | 60.74 | Low | 60.48 | High | 62.99 | Mkt Cap | 8.86B |
| Vol | 2.77M | Avg Vol | 1.91M | EPS | -2.36 | P/E | N/A | Forward P/E | -12.73 |
| Beta | 1.30 | Short Ratio | 6.44 | Inst. Own | 85.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-24 | 50-d Avg | 78.87 | 200-d Avg | 72.40 | 1yr Est | 107.23 |
| Income Statement | |||
| Total Revenue | 75.25M | ||
| Revenues (USD) | 75.25M | ||
| Gross Profit | 75.25M | ||
| Operating Expenses | 245.35M | ||
| Research and Development Expense | 198.22M | ||
| Selling, General and Administrative Expense | 47.12M | ||
| Operating Income | -170.09M | ||
| Interest Expense | 24.56M | ||
| Income Tax Expense | 11.00K | ||
| Net Income | -194.28M | ||
| Net Income Common Stock | -194.28M | ||
| Net Income Common Stock (USD) | -194.28M | ||
| Consolidated Income | -178.92M | ||
| Net Income to Non-Controlling Interests | 15.36M | ||
| Earnings per Basic Share | -1.36 | ||
| Earnings per Basic Share (USD) | -1.36 | ||
| Earnings per Diluted Share | -1.36 | ||
| Earning Before Interest & Taxes (EBIT) | -169.71M | ||
| Earning Before Interest & Taxes (USD) | -169.71M | ||
| Weighted Average Shares | 143.38M | ||
| Weighted Average Shares Diluted | 143.38M | ||
| Balance Sheet | |||
| Cash and Equivalents | 54.76M | ||
| Cash and Equivalents (USD) | 54.76M | ||
| Investments | 1.55B | ||
| Investments Current | 1.55B | ||
| Trade and Non-Trade Receivables | 8.56M | ||
| Current Assets | 1.67B | ||
| Property, Plant & Equipment Net | 428.97M | ||
| Total Assets | 2.11B | ||
| Debt Current | 45.32M | ||
| Total Debt | 1.38B | ||
| Current Liabilities | 283.35M | ||
| Debt Non-Current | 1.33B | ||
| Total Liabilities | 1.65B | ||
| Accumulated Retained Earnings (Deficit) | -1.92B | ||
| Accumulated Other Comprehensive Income | -1.23M | ||
| Shareholders Equity | 465.53M | ||
| Shareholders Equity (USD) | 465.53M | ||
| Assets Non-Current | 440.60M | ||
| Total Debt (USD) | 1.38B | ||
| Deferred Revenue | 126.34M | ||
| Goodwill and Intangible Assets | 5.59M | ||
| Liabilities Non-Current | 1.36B | ||
| Trade and Non-Trade Payables | 27.78M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 6.66M | ||
| Net Cash Flow from Financing | -449.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -134.24M | ||
| Capital Expenditure | -3.85M | ||
| Issuance (Purchase) of Equity Shares | 29.86M | ||
| Issuance (Repayment) of Debt Securities | -33.38M | ||
| Net Cash Flow from Investing | 43.68M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 47.54M | ||
| Net Cash Flow from Operations | -177.47M | ||
| Effect of Exchange Rate Changes on Cash | 477.00K | ||
| Share Based Compensation | 14.87M | ||